IP Library › Granted Patent US 12,196,758
Granted Patent B2
US 12,196,758 · App. 17/108,390 · Granted Jan 14, 2025

Method for the prognosis and treatment of cancer metastasis

Inventors: Roger Gomis (Barcelona, ES); Milica Pavlovic (Lajkovac, RS); Evarist Planet (Barcelona, ES); Anna Arnal (Barcelona, ES); Maria Tarragona (Barcelona, ES)
Assignee: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS
G01N33/5748C07K16/2875C12Q1/6886G01N33/57407G01N33/57415C07K2317/21C07K2317/76C12Q2600/112C12Q2600/118C12Q2600/158G01N2333/4706
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,196,758
App. No.
17/108,390
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.

Claims (37)

1. An in vitro method for diagnosing a subject with an increased risk of bone metastasis or recurrence of a triple negative or basal-like breast cancer in a subject suffering from said cancer and treating said subject to inhibit or prevent said bone metastasis or recurrence, comprising

i) quantifying the expression level of the c-MAF gene in a tumor sample of said subject, wherein the quantifying of the expression level comprises quantifying the messenger RNA (mRNA) of c-MAF, or a fragment of said mRNA, or quantifying the complementary DNA (cDNA) of c-MAF, or a fragment of said cDNA;

ii) comparing the expression level obtained in step i) with a reference value,

wherein increased expression level of said gene with respect to said reference value is indicative of increased risk of said subject developing bone metastasis or recurrence; and

iii) administering to said subject a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTOR inhibitor, a Src Kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject with an increased risk of bone metastasis or recurrence, and wherein the agent capable of avoiding and/or preventing the bone degradation is selected from the group consisting of a bisphosphonate, a RANKL inhibitor, PTH and PTHLH inhibitor or a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, and a cathepsin K inhibitor.

2. An in vitro method for predicting the clinical outcome of a subject suffering bone metastasis from a triple negative or basal-like breast cancer and further treating said subject, which comprises

i) quantifying the expression level of the c-MAF gene in a tumor sample of said subject, wherein the quantifying of the expression level comprises quantifying the messenger RNA (mRNA) of c-MAF, or a fragment of said mRNA, or quantifying the complementary DNA (cDNA) of c-MAF, or a fragment of said cDNA;

ii) comparing the expression level obtained in step i) with a reference value,

wherein increased expression level of said gene with respect to said reference value is indicative of a poor clinical outcome for said subject, wherein said subject has an increased expression level of said gene and is predicted to have a poor clinical outcome; and

iii) administering to said subject a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTOR inhibitor, a Src Kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to the subject if the subject is predicted to have a poor clinical outcome, and wherein the agent capable of avoiding and/or preventing the bone degradation is selected from the group consisting of a bisphosphonate, a RANKL inhibitor, PTH and PTHLH inhibitor or a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, and a cathepsin K inhibitor.

3. An in vitro method for designing a customized therapy for a subject suffering triple negative or basal-like breast cancer which comprises

i) quantifying the c-MAF gene expression level in a tumor sample of said subject, wherein the quantifying of the c-MAF gene expression level comprises quantifying the messenger RNA (mRNA) of c-MAF, or a fragment of said mRNA, or quantifying the complementary DNA (cDNA) of c-MAF, or a fragment of said cDNA;

ii) comparing the expression level obtained in i) with a reference value,

wherein if the expression level is increased with respect to said reference value, then said subject is susceptible to receive a therapy aiming to prevent and/or treat bone metastasis and/or bone degradation, wherein said subject has an increased expression level with respect to said reference value and is susceptible to receive the therapy aiming to prevent and/or treat bone metastasis and/or bone degradation; and

iii) administering to said subject a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTOR inhibitor, a Src Kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to the subject if the subject is susceptible to receive the therapy aiming to prevent and/or treat bone metastasis and/or bone degradation, and wherein the agent capable of avoiding and/or preventing the bone degradation is selected from the group consisting of a bisphosphonate, a RANKL inhibitor, PTH and PTHLH inhibitor or a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, and a cathepsin K inhibitor.

4. An in vitro method for determining the risk of bone metastasis in a subject suffering triple negative or basal-like breast cancer and further treating said subject, which comprises quantifying the expression level of the c-MAF gene in a sample of a said subject, wherein the quantifying of the expression level comprises quantifying the messenger RNA (mRNA) of c-MAF, or a fragment of said mRNA, or quantifying the complementary DNA (cDNA) of c-MAF, or a fragment of said cDNA, wherein when the expression level of said gene is above an average value plus one standard deviation it is indicative of an increased risk of early bone metastasis or recurrence, and administering to said subject a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTOR inhibitor, a Src Kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to the subject if the expression levels of said gene above the average value plus one standard deviation is indicative of an increased risk of early bone metastasis or recurrence, and wherein the agent capable of avoiding and/or preventing the bone degradation is selected from the group consisting of a bisphosphonate, a RANKL inhibitor, PTH and PTHLH inhibitor or a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, and a cathepsin K inhibitor, wherein the expression level of said gene in said subject is above the average value plus one standard deviation and is indicative of an increased risk of early bone metastasis or recurrence.

5. The method according to claim 1 , wherein the bone metastasis is osteolytic metastasis.

6. The method according to claim 1 , wherein the RANKL inhibitor is selected from the group consisting of a RANKL specific antibody, a RANKL-specific nanobody and osteoprotegerin.

7. The method according to claim 6 , wherein the RANKL specific antibody is denosumab and the RANKL specific nanobody is ALX-0141.

8. The method according to claim 1 , wherein the bisphosphonate is clodronate or zoledronic acid.

9. The method of claim 2 , wherein the bisphosphonate is clodronate or zoledronic acid.

10. The method of claim 3 , wherein the bisphosphonate is clodronate or zoledronic acid.

11. The method of claim 4 , wherein the bisphosphonate is clodronate or zoledronic acid.

12. The method according to claim 2 , wherein the bone metastasis is osteolytic metastasis.

13. The method according to claim 3 , wherein the bone metastasis is osteolytic metastasis.

14. The method according to claim 4 , wherein the bone metastasis is osteolytic metastasis.

15. The method of claim 1 , wherein the reference value is from a sample of a subject with breast cancer who has not suffered bone metastasis or that corresponds to the median value of the c-MAF gene expression level measured in a tumor tissue collection in biopsy samples of subjects with breast cancer who have not suffered metastasis.

16. The method of claim 2 , wherein the reference value is from a sample of a subject with breast cancer who has not suffered bone metastasis or that corresponds to the median value of the c-MAF gene expression level measured in a tumor tissue collection in biopsy samples of subjects with breast cancer who have not suffered metastasis.

17. The method of claim 3 , wherein the reference value is from a sample of a subject with breast cancer who has not suffered bone metastasis or that corresponds to the median value of the c-MAF gene expression level measured in a tumor tissue collection in biopsy samples of subjects with breast cancer who have not suffered metastasis.

18. The method according to claim 1 , wherein the estrogen receptor modulator inhibits the binding of estrogen to the estrogen receptor.

19. The method according to claim 2 , wherein the estrogen receptor modulator inhibits the binding of estrogen to the estrogen receptor.

20. The method according to claim 3 , wherein the estrogen receptor modulator inhibits the binding of estrogen to the estrogen receptor.

21. The method according to claim 4 , wherein the estrogen receptor modulator inhibits the binding of estrogen to the estrogen receptor.

22. The method according to claim 1 , wherein the estrogen receptor modulator is selected from the group consisting of progestogen, estradiol, droloxifene, raloxifene, lasofoxifene, TSE-424, tamoxifen, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, and SH646.

23. The method according to claim 2 , wherein the estrogen receptor modulator is selected from the group consisting of progestogen, estradiol, droloxifene, raloxifene, lasofoxifene, TSE-424, tamoxifen, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, and SH646.

24. The method according to claim 3 , wherein the estrogen receptor modulator is selected from the group consisting of progestogen, estradiol, droloxifene, raloxifene, lasofoxifene, TSE-424, tamoxifen, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, and SH646.

25. The method according to claim 4 , wherein the estrogen receptor modulator is selected from the group consisting of progestogen, estradiol, droloxifene, raloxifene, lasofoxifene, TSE-424, tamoxifen, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, and SH646.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: GOMIS, ROGER
To: FUNDACIÓ PRIVADA INSTITUT DE RECERCA BIOMÈDICA; FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Reel/Frame 055633/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: PAVLOVIC, MILICA; PLANET, EVARIST; ARNAL, ANNA; TARRAGONA, MARIA
To: FUNDACIÓ PRIVADA INSTITUT DE RECERCA BIOMÈDICA
Reel/Frame 055633/0015 →
CHANGE OF NAME Recorded Mar 18, 2021
From: FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS; FUNDACIÓ PRIVADA INSTITUT DE RECERCA BIOMÈDICA
To: INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS; FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA)
Reel/Frame 055634/0270 →
Priority Claims (1)
EP 123821399 · Apr 9, 2012 · regional
Continuity (6)
Division 15608036 · May 30, 2017
Division 14391085
Provisional Application 61732175 · Nov 30, 2012
Provisional Application 61724807 · Nov 9, 2012
Provisional Application 61621949 · Apr 9, 2012
Related Publication 20210190784A1 · Jun 24, 2021
References Cited (302)
US 6274338B1 · Glimcher et al. · 2001 [cited by applicant]
US 6740522B2 · Anderson et al. · 2004 [cited by applicant]
US 7019028B2 · Eder et al. · 2006 [cited by applicant]
US 7097834B1 · Boyle · 2006 [cited by applicant]
US 7364736B2 · Boyle et al. · 2008 [cited by applicant]
US 7411050B2 · Anderson · 2008 [cited by applicant]
US 8642270B2 · Leyland-Jones et al. · 2014 [cited by applicant]
US 9127302B2 · Verrant · 2015 [cited by applicant]
US 9134237B2 · Connelly et al. · 2015 [cited by applicant]
US 9702878B2 · Gomis et al. · 2017 [cited by applicant]
US 10006091B2 · Gomis et al. · 2018 [cited by applicant]
US 10047398B2 · Gomis et al. · 2018 [cited by applicant]
US 10114022B2 · Gomis et al. · 2018 [cited by applicant]
US 10119171B2 · Gomis et al. · 2018 [cited by applicant]
US 10793642B2 · Gomis et al. · 2020 [cited by applicant]
US 10866241B2 · Gomis · 2020 [cited by examiner]
US 11041213B2 · Gomis et al. · 2021 [cited by applicant]
US 11041861B2 · Gomis et al. · 2021 [cited by applicant]
US 11072831B2 · Gomis et al. · 2021 [cited by applicant]
US 11352673B2 · Gomis et al. · 2022 [cited by applicant]
US 11591599B2 · Gomis et al. · 2023 [cited by applicant]
US 11596642B2 · Gregory et al. · 2023 [cited by applicant]
US 11654153B2 · Gregory et al. · 2023 [cited by applicant]
US 20040138313A1 · Eder et al. · 2004 [cited by applicant]
US 20050181375A1 · Aziz et al. · 2005 [cited by applicant]
US 20080187909A1 · Dai et al. · 2008 [cited by applicant]
US 20080219996A1 · Kalebic et al. · 2008 [cited by applicant]
US 20080318240A1 · Nielsen et al. · 2008 [cited by applicant]
US 20090029378A1 · Connelly et al. · 2009 [cited by applicant]
US 20090048117A1 · Glimcher et al. · 2009 [cited by applicant]
US 20090220955A1 · Verrant · 2009 [cited by applicant]
US 20100113297A1 · Lidereau et al. · 2010 [cited by applicant]
US 20100210738A1 · Leyland-Jones et al. · 2010 [cited by applicant]
US 20110130296A1 · Benz et al. · 2011 [cited by applicant]
US 20110150979A1 · Ray et al. · 2011 [cited by applicant]
US 20110152113A1 · Escudero et al. · 2011 [cited by applicant]
US 20140057796A1 · Gomis et al. · 2014 [cited by applicant]
US 20140105918A1 · Gomis et al. · 2014 [cited by applicant]
US 20140162887A1 · Martin et al. · 2014 [cited by applicant]
US 20140303133A1 · Pietenpol et al. · 2014 [cited by applicant]
US 20140314792A1 · Gomis et al. · 2014 [cited by applicant]
US 20150152506A1 · Gomis et al. · 2015 [cited by applicant]
US 20150293100A1 · Gomis et al. · 2015 [cited by applicant]
US 20150362495A1 · Gomis et al. · 2015 [cited by applicant]
US 20160032399A1 · Gomis et al. · 2016 [cited by applicant]
US 20160032400A1 · Gomis et al. · 2016 [cited by applicant]
US 20160040247A1 · Gomis et al. · 2016 [cited by applicant]
US 20170002357A1 · Gomis et al. · 2017 [cited by applicant]
US 20170088900A1 · Anjamshoaa et al. · 2017 [cited by applicant]
US 20170101683A1 · Gomis et al. · 2017 [cited by applicant]
US 20170121777A1 · Gomis et al. · 2017 [cited by applicant]
US 20170369589A1 · Gomis et al. · 2017 [cited by applicant]
US 20170370935A1 · Gomis et al. · 2017 [cited by applicant]
US 20190119757A1 · Gomis et al. · 2019 [cited by applicant]
US 20190169693A1 · Gomis et al. · 2019 [cited by applicant]
US 20190242898A1 · Gomis et al. · 2019 [cited by applicant]
US 20190256922A1 · Gomis et al. · 2019 [cited by applicant]
US 20190269707A1 · Gregory et al. · 2019 [cited by applicant]
US 20190309299A1 · Gomis et al. · 2019 [cited by applicant]
US 20210137952A1 · Gregory et al. · 2021 [cited by applicant]
US 20210317534A1 · Gomis et al. · 2021 [cited by applicant]
US 20210388452A1 · Gomis et al. · 2021 [cited by applicant]
US 20220042997A1 · Gomis et al. · 2022 [cited by applicant]
US 20220049316A1 · Gomis et al. · 2022 [cited by applicant]
US 20230323356A1 · Gomis et al. · 2023 [cited by applicant]
BR 112013008505A2 · 2016 [cited by applicant]
CN 1886138A · 2006 [cited by applicant]
CN 103339265A · 2013 [cited by applicant]
EP 0120694A2 · 1984 [cited by applicant]
EP 0125023A1 · 1984 [cited by applicant]
EP 1961825A1 · 2008 [cited by applicant]
EP 2626431A2 · 2013 [cited by applicant]
EP 2650682A1 · 2013 [cited by applicant]
JP 2007527247A · 2007 [cited by applicant]
JP 2010518878A · 2010 [cited by applicant]
JP 2010527620A · 2010 [cited by applicant]
WO WO9116880A1 · 1991 [cited by applicant]
WO WO0055126A2 · 2000 [cited by applicant]
WO WO0149288A1 · 2001 [cited by applicant]
WO WO03020278A1 · 2003 [cited by applicant]
WO WO03020721A1 · 2003 [cited by applicant]
WO WO03059249A2 · 2003 [cited by applicant]
WO WO2004000843A1 · 2003 [cited by applicant]
WO WO2004014888A1 · 2004 [cited by applicant]
WO WO2005029067A2 · 2005 [cited by applicant]
WO WO2005046731A1 · 2005 [cited by applicant]
WO WO2005063252A1 · 2005 [cited by applicant]
WO WO2005086891A2 · 2005 [cited by applicant]
WO WO2006012221A2 · 2006 [cited by applicant]
WO WO2006135436A2 · 2006 [cited by applicant]
WO WO2008098351A1 · 2008 [cited by applicant]
WO WO2008104543A2 · 2008 [cited by applicant]
WO WO2008142164A2 · 2008 [cited by applicant]
WO WO2008145125A1 · 2008 [cited by applicant]
WO WO2009045115A1 · 2009 [cited by applicant]
WO WO2009049410A1 · 2009 [cited by applicant]
WO WO2009146546A1 · 2009 [cited by applicant]
WO WO2010000907A1 · 2010 [cited by applicant]
WO WO2010136569A1 · 2010 [cited by applicant]
WO WO2012045905A2 · 2012 [cited by applicant]
WO WO2012125828A2 · 2012 [cited by applicant]
WO WO2013153458A2 · 2013 [cited by applicant]
WO WO2013182912A2 · 2013 [cited by applicant]
WO WO2014057357A2 · 2014 [cited by applicant]
WO WO2014140896A2 · 2014 [cited by applicant]
WO WO2014140933A2 · 2014 [cited by applicant]
WO WO2014184679A2 · 2014 [cited by applicant]
WO WO2015052583A2 · 2015 [cited by applicant]
WO WO2016092524A1 · 2016 [cited by applicant]
WO WO2017203468A1 · 2017 [cited by applicant]
WO WO2019102380A1 · 2019 [cited by applicant]
Lacerna et al (Seminars in Oncology, 2003, 30(5)(suppl 16): 150-160). [cited by examiner]
Parr et al (Clinical Cancer Research, 2004, 10: 202-211). [cited by examiner]
Abbott Molecular, “Vysis LSI IGH/MAF Dual Color Dual Fusion Probe,” accessed at http://abbottmolecular.com/us/products/analyte-specific-reagent/fish/vysis-lsi-igh-maf-dual-color-dual-fusion-probe.html, accessed on Oct. … [cited by applicant]
Abnova, “MAF FISH Probe,” accessed at http://abnova.com/products/products_detail.asp?Catalog_id=FA0375, accessed on Oct. 16, 2014, 2 pages. [cited by applicant]
Afinitor.com, “AFINITOR (everolimus) Tablets,” accessed at http://afinitor.com/sega-tuberous-sclerosis/patient/sega-information.jsp, accessed on Oct. 16, 2014, 5 pages. [cited by applicant]
Agilent Technologies, “Probes for Chromosome 16,” accessed at http://genomics.agilent.com/productSearch.jsp?chr=16&start=79483700&end=79754340&_requestid=78075, accessed on Oct. 16, 2014, 3 pages. [cited by applicant]
Al-Mulla, F., et al., “Expressive Genomic Hybridisation: Gene Expression Profiling at the Cytogenetic Level,” Journal of Clinical Pathology: Molecular Pathology 56(4):210-217, BMJ Publishing Group, England (2003). [cited by applicant]
Altschul, S.F., et al., “Basic Local Alignment Search Tool,” Journal of Molecular Biology 215(3):403-410, Elsevier, England (Oct. 1990). [cited by applicant]
Andrews, N.C., et al., “The Ubiquitous Subunit of Erythroid Transcription Factor NF-E2 is a Small Basic-leucine Zipper Protein Related to the v-maf Oncogene,” Proceedings of the National Academy of Sciences of USA 90(24… [cited by applicant]
ARUP Laboratories, “Multiple Myeloma (MM) by FISH: Detection of Prognostically Significant Genomic Aberrations in Multiple Myeloma (MM) by Fluorescence in situ Hybridization (FISH),” accessed at http://aruplab.com, acce… [cited by applicant]
AZURE Trial Protocol for: Coleman, R.E., et al., “Breast-Cancer Adjuvant Therapy with Zoledronic Acid,” The New England Journal of Medicine 365(15):1396-1405, Massachusetts Medical Society, United States, 144 pages (201… [cited by applicant]
Badve, S., et al. “Basal-like and Triple-negative Breast Cancers: A Critical Review with an Emphasis on the Implications for Pathologists and Oncologists,” Modern Pathology 24(2):157-167, USCAP, Inc., United States (201… [cited by applicant]
Barrett, T., et al., “NCBI GEO: Mining Tens of Millions of Expression Profiles—Database and Tools Update,” Nucleic Acids Research 35(Database Issue):D760-D765, Oxford University Press, England (2007). [cited by applicant]
Baselga, J., et al., “Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer,” The New England Journal of Medicine 366(6):520-529, Massachusetts Medical Society, United States (2012). [cited by applicant]
Bertucci, F., et al., “How Basal are Triple-Negative Breast Cancers?,” International Journal of Cancer 123(1):236-240, Wiley-Liss, United States (2008). [cited by applicant]
Bogado, C.E., et al., “Denosumab: An Update,” Drugs of Today 47(8):605-613, Prous Science, United States (2011). [cited by applicant]
Bohn, O.L., et al., “Biomarker Profile in Breast Carcinomas Presenting with Bone Metastasis,” International Journal of Clinical and Experimental Pathology 3(2):139-146, E-Century Publishing Corporation, United States (2… [cited by applicant]
Bos, P.D., et al., “Genes that Mediate Breast Cancer Metastasis to the Brain,” Nature 459(7249):1005-1009, Nature Publishing Group, England (2009). [cited by applicant]
Bowles, D.W., et al., “Multi-targeted Tyrosine Kinase Inhibitors in Clinical Development: Focus on XI-184 (Cabozantinib),” Drugs of today (Barcelona, Spain) 47(11):857-868, Clarivate Analytics, Spain (Nov. 2011). [cited by applicant]
Brufsky, A.M., “The Evolving Role of Bone-Conserving Therapy in Patients with Breast Cancer,” Semin. Oncol. 37(Suppl 1):S12-S19, W.B. Saunders, United States (2010). [cited by applicant]
Cancer Genome Atlas Network, “Comprehensive Molecular Portraits of Human Breast Tumors,” Nature 490(7418):61-70, Nature Publishing Group, England (2012). [cited by applicant]
Carey, L.A., “Triple-Negative (basal-like) Breast Cancer: A New Entity,” Breast Cancer Research 9(Suppl1):S13, BioMed Central Ltd., England (2007). [cited by applicant]
CGI Italia, “IGH/MAF Two Color, Two Fusion Translocation Probe,” accessed at http://cancergeneticsitalia.com/dna-fish-probe/ighmaf/, accessed on Oct. 16, 2014, 1 page. [cited by applicant]
Choi, M., et al., “Genetic Diagnosis by Whole Exome Capture and Massively Parallel DNA Sequencing,” Proceedings of the National Academy of Sciences of USA 106(45):19096-19101, National Academy of Sciences, United States… [cited by applicant]
ClinicalTrials.gov, “Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE),” Identifier NCT01077154, accessed at https://clinicaltrials.… [cited by applicant]
Coleman, R., et al., “Adjuvant Zoledronic Acid in Patients with Early Breast Cancer: Final Efficacy Analysis of the AZURE (BIG 01/04) Randomised Open-label Phase 3 Trial,” The Lancet Oncology 15(9):997-1006, Lancet Publ… [cited by applicant]
Coleman, R.E., et al., “Breast-Cancer Adjuvant Therapy with Zoledronic Acid,” The New England Journal of Medicine 365(15):1396-1405, Massachusetts Medical Society, United States (2011). [cited by applicant]
Creative Bioarray, “IGH/MAF Translocation, Dual Fusion Probe,” accessed at http://www.creative-bioarray.com/IGH-MAF-Translocation,-Dual-Fusion-Probe-FHPC-066-item-4707.htm, accessed on May 21, 2015, 2 pages. [cited by applicant]
Curtis, C., et al., “The Genomic and Transcriptomic Architecture of 2,000 Breast Tumours Reveals Novel Subgroups,” Nature 486(7403):346-352, Nature Publishing Group, England (2012). [cited by applicant]
Cytocell, “Oncology and Constitutional FISH Probe Catalogue 2012/2013,” accessed at http://zentech.be/uploads/docs/products_info/prenatalogy/cytocell%202012-2013%20catalogue%5B3%5D.pdf, accessed on Oct. 16, 2014, 134 pa… [cited by applicant]
Dako Denmark A/S, “HER2 IQFISH pharmDxTM, Code K5731,” Assay Information, 3rd edition, 184 pages. [cited by applicant]
Dako, “SureFISH Probes,” accessed at http://dako.com/us/ar42/psg42806000/baseproducts_surefish.htm?setCountry=true&purl=ar42/psg42806000/baseproducts_surefish.htm?undefined&submit=Accept%20country, accessed on Oct. 16, … [cited by applicant]
Dannhardt, G. and Kiefer, W., “Cyclooxygenase Inhibitors—Current Status and Future Prospects,” European Journal of Medicinal Chemistry 36(2):109-126, Editions Scientifiques et Medicales Elsevier SAS, France (2001). [cited by applicant]
Dean-Colomb, W., et al., “Elevated Serum P1NP Predicts Development of Bone Metastasis and Survival in Early-Stage Breast Cancer,” Breast Cancer Research and Treatment 137(2):631-636, Springer Science+Business Media, Uni… [cited by applicant]
Demarest, J.F., et al., “Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5,” Retrovirology 2(Suppl 1):S13, BioMed Central, England (2005). [cited by applicant]
Dhesy-Thind, S., et al., “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline,” J Clin Oncol 35, … [cited by applicant]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Adjuvant Bisphosphonate Treatment in Early Breast Cancer: Meta-analyses of Individual Patient Data From Randomised Trials,” Lancet 386(10001):1353-1361, Else… [cited by applicant]
Ettenberg, S.A., et al., “BHQ880, A Novel Anti-DKK1 Neutralizing Antibody, Inhibits Tumor-Induced Osteolytic Bone Disease,” Proceedings of the American Association for Cancer Research 49:947, Abstract 3987, American Ass… [cited by applicant]
Extended European Search Report for EP Application No. 12382139.9, European Patent Office, Munich, Germany, dated Sep. 20, 2012, 8 pages. [cited by applicant]
Extended European Search Report for EP Application No. 15180897.9, European Patent Office, Munich, Germany, mailed Sep. 29, 2016, 9 pages. [cited by applicant]
Eychene, A., et al., “A NewMAFia in Cancer,” Nature Reviews Cancer 8(9):683-693, Nature Publishing Group, England (2008). [cited by applicant]
Fili, S., et al., “Therapeutic Implications of Osteoprotegerin,” Cancer Cell International 9:26:1-8, BioMed Central Ltd., England (2009). [cited by applicant]
Finn, R.S., et al., “Targeting the Cyclin-dependent Kinases (CDK) 4/6 in Estrogen Receptor-positive Breast Cancers,” Breast Cancer Research 18(1):17, BioMed Central Ltd., England, 11 pages (2016). [cited by applicant]
Fornier, M.N., et al., “Phase I Dose-finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors,” Clinical Cancer Research 13(19):5841-5846, The Association, United States (Oct. 2… [cited by applicant]
Fujiwara, K.T., et al., “Two New Members of the [cited by applicant]
GenBank Database, “ [cited by applicant]
GenBank Database, “ [cited by applicant]
GenBank Database, “ [cited by applicant]
GenBank Database, “ [cited by applicant]
GenBank Database, “ [cited by applicant]
Gene Expression Omnibus Database, Accession No. GSE 12276, made public on Jun. 13, 2009, accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12276, accessed on Jun. 20, 2013, 2 pages. [cited by applicant]
Gene Expression Omnibus Database, Accession No. GSE 14020, made public on May 1, 2009, accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14020, accessed on Jun. 20, 2013, 2 pages. [cited by applicant]
Gene Expression Omnibus Database, Accession No. GSE 2034, made public on Feb. 23, 2005, accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc/cgi?acc=GSE+2034, accessed on Jun. 20, 2013, 7 pages. [cited by applicant]
Gene Expression Omnibus Database, Accession No. GSE 2603, made public on Jul. 28, 2005, accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc/cgi?acc=GSE+2603, accessed on Jun. 20, 2013, 2 pages. [cited by applicant]
GenPept Database, “RecName: Full=Transcription Factor Maf; AltName: Full=Proto-oncogene c-Maf; AltName: Full=V-maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog [ [cited by applicant]
GenPept Database, “Transcription Factor Maf Isoform a [ [cited by applicant]
GenPept Database, “Transcription Factor Maf Isoform b [ [cited by applicant]
Gentleman, R.C., et al., “Bioconductor: Open Software Development for Computational Biology and Bioinformatics,” Genome Biology 5(10):R80, 16 pages, BioMed Central Ltd, England (2004). [cited by applicant]
Genycell Biotech, “FISH Mieloma Multiple,” accessed at http://google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=CCQQFjAA&url=http%3A%2F%2Fwww.genycell.es%2Fimages%2Fproductos%2Fbrochures%2Flphmie6_86.ppt&ei=MhFYUO… [cited by applicant]
Giancotti, V., “Breast Cancer Markers,” Cancer Letters, 243(2):145-159, Elsevier Ireland Ltd., Ireland (2006). [cited by applicant]
Gnant, M., et al., “Adjuvant Bisphosphonates in Endocrine-responsive Breast Cancer: What is their Place in Therapy?” Therapeutic Advances in Medical Oncology 1(3):123-136, Sage, England (2009). [cited by applicant]
Goss, P.E., and Chambers, A.F., “Does Tumour Dormancy Offer a Therapeutic Target?,” Nature Reviews. Cancer 10(12):871-877, Macmillan Publishers Ltd., England (2010). [cited by applicant]
Gur-Dedeoglu, B., et al., “A Resampling-Based Meta-Analysis for Detection of Differential Gene Expression in Breast Cancer,” BMC Cancer 8:396, BioMed Central Ltd, England (2008), 16 pages. [cited by applicant]
Hadji, P., et al., “Adjuvant Bisphosphonates in Early Breast Cancer: Consensus Guidance for Clinical Practice From a European Panel,” Annals of Oncology 27(3):379-390, Oxford University Press, England (2016). [cited by applicant]
Hammond, M.E.H., et al., “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer,” Journa… [cited by applicant]
Henry, D.H., et al., “Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma,” … [cited by applicant]
Hiraga, T., “Role of Cyclooxygenase-2 in the Bone Metastasis of the Breast Cancer [Nyugan No Honeteni Ni Okeru Shikurookishigenaze-2 No Yakuwari],” Bone 20(5):563-566, Japan (2006). [cited by applicant]
Hospira Healthcare Corporation, “Prescribing Information: Zoledronic Acid for Injection, 4 mg/5 ml (0.8 mg/mL), zoledronic acid (as zoledronic acid monohydrate),” Control No. 182128, prepared May 4, 2015, accessed at ht… [cited by applicant]
Hu, G., et al., “MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer,” Cancer Cell 15(1):9-20, Cell Press, United States (2009). [cited by applicant]
Huang, Q. and Ouyang, X., “Biochemical-Markers for the Diagnosis of Bone Metastasis: A Clinical Review,” Cancer Epidemiology 36(1):94-98, Elsevier Ltd., Netherlands (2012). [cited by applicant]
Huober J and Thurlimann B, “Bone Targeted Therapy in Breast Cancer: Present and Future,” Critical Reviews in Oncology/Hematology 74 Suppl 1:S7-S10, Elsevier Scientific Publishers, Netherlands (Apr. 2010). [cited by applicant]
Hurt, E.M., et al., “Overexpression of c-maf is a Frequent Oncogenic Event in Multiple Myeloma that Promotes Proliferation and Pathological Interactions with Bone Marrow Stroma,” Cancer Cell 5(2):191-199, Cell Press, Un… [cited by applicant]
Igarashi, K., et al., “Activity and Expression of Murine Small Maf Family Protein MafK,” The Journal of Biological Chemistry 270(13):7615-7624, The American Society for Biochemistry and Molecular Biology, Inc., United S… [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/ES2011/070693, International Bureau of WIPO, Sweden, mailed on Apr. 9, 2013, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/IB2013/001204, European Patent Office, Rijswijk, Netherlands, mailed on Aug. 11, 2014, 35 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/ES2011/070693, European Patent Office, Netherlands, mailed on Apr. 2, 2012, 12 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2013/001204, European Patent Office, Rijswijk, Netherlands, mailed on Dec. 17, 2013, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2014/002675, mailed on Jun. 3, 2015,17 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2014/002675, The International Bureau of WIPO, Geneva, Switzerland, issued Apr. 12, 2016, 12 pages. [cited by applicant]
Kang, Y., et al., “A Multigenic Program Mediating Breast Cancer Metastasis to Bone,” Cancer Cell 3(6):537-549, Cell Press, United States (2003). [cited by applicant]
Kataoka, K., et al., “Small Maf Proteins Heterodimerize with Fos and May Act as Competitive Repressors of the NF-E2 Transcription Factor,” Molecular and Cellular Biology 15(4):2180-2190, American Society for Microbiolog… [cited by applicant]
Kataoka, K., et al., “Transactivation Activity of Maf Nuclear Oncoprotein is Modulated by Jun, Fos and Small Maf Proteins,” Oncogene 12:53-62, Stockton Press, England (1996). [cited by applicant]
Kharaishvili, G., et al., “Collagen Triple Helix Repeat Containing 1 Protein, Periostin and Versican in Primary and Metastatic Breast Cancer: An Immunohistochemical Study,” Journal of Clinical Pathology 64(11):977-982, … [cited by applicant]
Klopocki, E. and Mundlos, S., “Copy-number Variations, Noncoding Sequences, and Human Phenotypes,” Annual Review of Genomics and Human Genetics 12:53-72, Annual Reviews, United States (2011). [cited by applicant]
Knight III, W.A., et al., “Estrogen Receptor as an Independent Prognostic Factor for Early Recurrence in Breast Cancer,” Cancer Research 37(12):4669-4671, American Association for Cancer Research, United States (1977). [cited by applicant]
Kohler, G. and Milstein, C., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256(5517):495-497, Macmillan Journals Ltd., England (Aug. 1975). [cited by applicant]
Kuritzkes, D.R., “HIV-1 Entry Inhibitors: An Overview,” Current Opinion in HIV and AIDS 4(2):82-87, Lippincott Williams & Wilkins, United States (2009). [cited by applicant]
Largo, C., et al., “Identification of Overexpressed Genes in Frequently Gained/Amplified Chromosome Regions in Multiple Myeloma,” Haematologica 91(2):184-191, Ferrata Storti Foundation, Italy (2006). [cited by applicant]
Leica Biosystems, “KreatechTMFISH Probes,” accessed at http://leicabiosystems.com/ihc-ish/kreatech-fish-probes/, accessed on Oct. 16, 2014, 2 pages. [cited by applicant]
Liepe, K, “Abstract: Alpharadin, a 223Ra-based Alpha-particle-emitting Pharmaceutical for the Treatment of Bone Metastases in Patients With Cancer,” Current Opinion in Investigational Drugs 10(12):1346-1358, Thomson Reu… [cited by applicant]
Lipton, A., et al., “The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors,” J Natl Compr Canc Netw 7(Suppl 7):S1-30, Jones and Bartlett Publishers, United … [cited by applicant]
Maisano, R., et al. , “Novel Therapeutic Approaches to Cancer Patients with Bone Metastasis,” Critical Reviews in Oncology/ Hematology 40(3):239-250, Elsevier Science Ireland Ltd., Ireland (2001). [cited by applicant]
MetaSystems, “24XCyte,” accessed at http://metasystems-international.com/index.php?option=com_joodb&view=article&joobase=5*id=12%3Ad-5029-100-og&Itemid=272, accessed on Oct. 16, 2014, 2 pages. [cited by applicant]
Ministry of Health, Social Services and Equality, Data Sheet of “Zoledronic acid Kern Pharma 4 mg/100 mL Solution for Infusion EFG,” Text Revised Jul. 2016, Machine-translated Jul. 6, 2017, 38 pages (Ministerio de Sanid… [cited by applicant]
Mystakidou, K., et al., “Randomized, Open Label, Prospective Study on the Effect of Zoledronic Acid on the Prevention of Bone Metastases in Patients with Recurrent Solid Tumors That Did Not Present with Bone Metastases … [cited by applicant]
Nakashima, T., et al., “New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells,” Clinical Cancer Research 16(10):2792-2… [cited by applicant]
Neville-Webbe H.L. and Coleman R.E., “Bisphosphonates and RANK Ligand Inhibitors for the Treatment and Prevention of Metastatic Bone Disease,” European Journal of Cancer 46(7):1211-1222, Elsevier Science Ltd., England (… [cited by applicant]
Ng, P.C. and Kirkness, E.F., “Whole Genome Sequencing,” Methods in Molecular Biology 628:215-226, Springer Science+Business Media, LLC, Netherlands (2010). [cited by applicant]
Nguyen, D.X. and Massague, J., “Genetic Determinants of Cancer Metastasis,” Nature Reviews Genetics 8(5):341-352, Nature Publishing Group, England (2007). [cited by applicant]
Nguyen, D.X., et al., “Metastasis: From Dissemination to Organ-Specific Colonization,” Nature Reviews Cancer 9(4):274-284, Macmillan Publishers Limited, England (2009). [cited by applicant]
Pageau, S.C., “Denosumab,” Monoclonal Antibodies 1(3):210-215, Landes Bioscience, United States (2009). [cited by applicant]
Paik, S., et al., “A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer,” The New England Journal of Medicine 351(27):2817-2826, Massachusetts Medical Society, United States (2004). [cited by applicant]
Paterson, A.H.G. and Shea-Budgell, M.A., “Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline,” Journal of Clinical Medicine 2(4):283-301, MDPI AG, Switzerland (2013). [cited by applicant]
Paterson, A.H.G., et al., “Oral Clodronate for Adjuvant Treatment of Operable Breast Cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A Multicentre, Placebo-controlled, Randomised Trial,” The … [cited by applicant]
Pavlovic, M., et al., “Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis,” Journal of the National Cancer Institute 107(12):djv256:1-12, Oxford University Press, United States (2015). [cited by applicant]
Polascik, T.J., “Bisphosphonates in Oncology: Evidence for the Prevention of Skeletal Events in Patients with Bone Metastases,” Drug Design, Development and Therapy 3:27-40, Dove Medical Press Ltd., New Zealand (2009). [cited by applicant]
Pollack, J.R., et al., “Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors,” Proceedings of the National Academy of Sciences of USA 99(20)… [cited by applicant]
Rocques, N., et al., “GSK-3-Mediated Phosphorylation Enhances Maf-Transforming Activity,” Molecular Cell 28(4):584-597, Cell Press, United States (2007). [cited by applicant]
Rojo, F., et al., “Nuclear PARP-1 Protein Overexpression is Associated with Poor Overall Survival in Early Breast Cancer,” Annals of Oncology 23(5):1156-1164, Oxford University Press, England (2012). [cited by applicant]
Rotstein, D.M., et al., “Spiropiperidine CCR5 Antagonists,” Bioorganic and Medicinal Chemistry Letters 19(18):5401-5406, Elsevier Ltd., England (2009). [cited by applicant]
Santana-Codina, N., et al., “A Transcriptome-proteome Integrated Network Identifies Endoplasmic Reticulum Thiol Oxidoreductase (ERp57) as a Hub that Mediates Bone Metastasis,” Molecular and Cellular Proteomics 12(8):211… [cited by applicant]
Sen, B. and Johnson, F.M., “Regulation of SRC Family Kinases in Human Cancers,” Journal of Signal Transduction 2011(865819):1-14, Hindawi Publishing Corporation, United States (Apr. 2011). [cited by applicant]
Supplementary Appendix for: Coleman, R.E., et al., “Breast-Cancer Adjuvant Therapy with Zoledronic Acid,” The New England Journal of Medicine 365(15):1396-1405, Massachusetts Medical Society, United States (2011), 18 pa… [cited by applicant]
Sutherland, R.L., et al., “Expression and Regulation of Cyclin Genes in Breast Cancer,” Acta Oncologica 34(5):651-656, Scandinavian University Press, England (1995). [cited by applicant]
Swennenhuis, J.F., et al., “Construction of Repeat-Free Fluorescence in situ Hybridization Probes,” Nucleic Acids Research 40(3):e20:1-8, Oxford University Press, England (Feb. 2012). [cited by applicant]
Takahashi, S., “Anti-RANKL Antibody for Treatment of Patients with Bone Metastasis from Breast Cancer,” Gan To Kagaku Ryoho 39(1):89-94, Gan To Kagaku Ryohosha, Tokyo, Japan (2012). [cited by applicant]
Thery, C., et al., “Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids,” Current Protocols in Cell Biology Chapter 3:3.22.1-3.22.29, Oxford University Press, England (2006). [cited by applicant]
U.S. Appl. No. 61/801,769, filed Mar. 15, 2013, inventor Gomis. [cited by applicant]
Velasco-Velazquez, M., et al., “CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells,” Cancer Research 72(15):3839-3850, American Association for Cancer Research, United States (Aug. 2012). [cited by applicant]
Washam, C.L., et al., “Identification of PTHrP(12-48) as a Plasma Biomarker Associated with Breast Cancer Bone Metastasis,” Cancer Epidemiology, Biomarkers and Prevention 22(5):972-983, American Association for Cancer R… [cited by applicant]
Weber-Mangal, S., et al., “Breast Cancer in Young Women (≤35 years): Genomic Aberrations Detected by Comparative Genomic Hybridization,” International Journal of Cancer 107(4):583-592, Wiley-Liss, Inc., United States (2… [cited by applicant]
Winer, E.P., et al., “Activity of Cabozantinib (XL184) in Metastatic Breast Cancer (MBC): Results From a Phase 2 Randomized Discontinuation Trial (RDT),” Annual Meeting of the American Society of Clinical Oncology, Chic… [cited by applicant]
Zeiss, “Fish Probes: XL Haematology,” accessed at https://micro-shop.zeiss.com/?440675675dedc6&1=en&p=uk&f=r&i=5000&o=&h=25&n=1&sd=000000-528-231-uk, accessed on Oct. 16, 2014, 3 pages. [cited by applicant]
Zhang, X.H-F., et al., “Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals,” Cancer Cell 16(1):67-78, Cell Press, United States (2009). [cited by applicant]
Zhou, H., et al., “Updates of mTOR Inhibitors,” Anticancer Agents in Medicinal Chemistry 10(7):571-581, Bentham Science Publishers, Netherlands (2010). [cited by applicant]
ZOMETA®, “About ZOMETA® (zoledronic acid) 4 mg/5 mL Injection,” accessed at http://www.us.zometa.com/index.jsp?usertrack.filter_applied=true&NovaId=29353769344676433633, accessed on Apr. 3, 2015, 2 pages. [cited by applicant]
Coleman, R., et al., “Impact of MAF Gene Amplification on Disease Recurrence and Effects of Adjuvant Zoledronic Acid in Early Breast Cancer,” Cancer Research 77(4 Suppl):Abstract P1-09-01, Proceedings of the 2016 San An… [cited by applicant]
Coleman, R., et al., “Effect of MAF Amplification on Treatment Outcomes with Adjuvant Zoledronic Acid in Early Breast Cancer: A Secondary Analysis of the International, Open-Label, Randomised, Controlled, Phase 3 AZURE … [cited by applicant]
Gnant, M., et al., “Adjuvant Endocrine Therapy Plus Zoledronic Acid in Premenopausal Women With Early-stage Breast Cancer: 62-month Follow-up From the ABCSG-12 Randomised Trial,” The Lancet Oncology 12(7):631-641, Lance… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2017/053094, European Patent Office, Rijswijk, Netherlands, mailed on Aug. 14, 2017, 19 pages. [cited by applicant]
Kim, H., et al., “Multi-cancer Computational Analysis Reveals Invasion-associated Variant of Desmoplastic Reaction Involving INHBA, THBS2 and COL11A1,” BMC Medical Genomics 3:51, BioMed Central Ltd., England, 11 pages (… [cited by applicant]
Morito, N., et al., “Overexpression of c-Maf Contributes to T-Cell Lymphoma in Both Mice and Human,” Cancer Research 66(2):812-819, American Association for Cancer Research, Japan (Jan. 2006). [cited by applicant]
Office Action (Non-Final) mailed Jul. 14, 2016, in U.S. Appl. No. 14/391,085, Gomis, R. et al., § 371(c) Date Oct. 7, 2014, 10 pages. [cited by applicant]
Pavlovic, M., et al., “Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis,” Journal of the National Cancer Institute 107(12):djv256:S1-S32, Supplementary Figures 1-5, Oxford University Press, United Stat… [cited by applicant]
Bruland Ø.S., et al., “High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the Alpha-emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?,” Clinical Cancer Research, 12 (20 Pt 2):625… [cited by applicant]
Co-pending Application, U.S. Appl. No. 15/944,510, inventors Gomis R., et al., filed Apr. 3, 2018 (Not Published). [cited by applicant]
Co-pending Application, U.S. Appl. No. 15/955,790, Inventors Gomis, R., et al., filed Apr. 18, 2018 (Not Published). [cited by applicant]
Creative Bioarray, “Products,” accessed at http://creative-bioarray.com/Products.htm, accessed on Oct. 16, 2014, 2 pages. [cited by applicant]
Gralow, J., et al., “Phase III Trial of Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology Study S0307,” ASCO meeting library, accessed at http… [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/IB2017/053094, mailed on Sep. 3, 2018, 23 pages. [cited by applicant]
Coleman, R.E., et al., “Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04),” Journal of Bone Oncology, 13(1… [cited by applicant]
Costa, L and Ferreira, A.R., “Adjuvant zoledronic acid to treat breast cancer: not for all,” The Lancet Oncology, 18(11):1437-1439, The Lancet Publishing Group, England (Nov. 2017). [cited by applicant]
Haas, M.J., RANKLing Non-skeletal Tumors, Prospects, Targets and Mechanisms, SciBX, Nature Publishing Group, 2 pages, (2010). [cited by applicant]
Horlings, H.M., et al., “Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients,” Clinical Cancer Research, 16(2):651-663, The Association, United States (Jan. 201… [cited by applicant]
Liao, S., et al., “Identification of New Breast Cancer Candidate Genes Associated with Stromal Invasion,” Cancer Research, Abstract #4036, 69(2 Suppl), (Jan. 2009), Retrieved from the Internet http://cancerres.aacrjourn… [cited by applicant]
Stopeck, A.T., et al., “Denosumab Compared with Zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double-Blind Study,” Journal of Clinical Oncology 28(35): 5132-… [cited by applicant]
Van de Wetering de Rooij, J., et al., “Safety, Pharmacokinetics and Efficacy of Anti-Rankl Nanobody® Alx-0141 in Healthy Postmenopausal Women,” Annals of the Rheumatic Diseases 70(Suppl.3):136, 2011 (Abstract). [cited by applicant]
Yakes F.M., et al., “Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth,” Molecular Cancer Therapeutics 10(12):2298-2308, American Association for… [cited by applicant]
Co-pending Application, U.S. Appl. No. 16/766,043, inventors Gomis R., et al., filed Nov. 21, 2018 (Not Published). [cited by applicant]
Annunziata, C.M., et al., “A Mechanistic Rationale for MEK Inhibitor Therapy in Myeloma Based on Blockade of MAF Oncogene Expression,” Blood, 117(8):2396-2404, American Society of Hematology, United States (Feb. 2011). [cited by applicant]
Extended European Search Report for EP Application No. 19165007, The Hague, Netherlands, mailed on May 22, 2019, 15 pages. [cited by applicant]
Extended European Search Report for EP Application No. 19159414, Munich, Germany, mailed on Jun. 13, 2019, 10 pages. [cited by applicant]
Gnant, M., et al., “Adjuvant Denosumab in Breast Cancer (ABCSG-18): a Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial,” Lancet, 386(9992):433-443, Elsevier, England (Aug. 2015). [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2018/059189, mailed on May 7, 2019, 32 pages. [cited by applicant]
Johnson, K., “Denosumab Boosts Survival, Not Just Bones, in Breast Cancer,” Medscape, Retrieved on [Apr. 23, 2019], Dec. 10, 2015, Retrieved From the Internet: (URL: https://www.medscape.com/viewarticle/855803), 2 pages. [cited by applicant]
Stein, C.A. and Cohen, J.S., “Oligodeoxynucleotides as Inhibitors of Gene Expression: a Review,” Cancer Research 48(10):2659-2668, American Association for Cancer Research, United States (1988). [cited by applicant]
Yersal, O and Barutca, S., “Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications,” World Journal of Clinical Oncology, 5(3):412-424, Baishideng Publishing Group, United States (Aug. 2014). [cited by applicant]
Office action mailed Jan. 28, 2020, in U.S. Appl. No. 15/608,036, filed May 30, 2017, inventor Gomis; R., et al., 6 pages. [cited by applicant]
Office action mailed Apr. 26, 2019, in U.S. Appl. No. 15/608,036, filed May 30, 2017, inventor Gomis; R., et al., 19 pages. [cited by applicant]
Office action mailed Jan. 10, 2019, in U.S. Appl. No. 15/608,036, filed May 30, 2017, inventor Gomis; R., et al., 14 pages. [cited by applicant]
Deeks, E.D., et al., “Zoledronic acid: a review of its use in the treatment of osteoporosis,” Drugs Aging 25(11):963-986, SpringerLink, Germany (2008). [cited by applicant]
Pavlovic, M., “Identification of genetic determinants of breast cancer metastasis to the bone,” Doctoral Thesis and Supplementary Materials and Methods, University Pompeu Fabra, Spain, 241 pages (2013). [cited by applicant]
Paterson, A., et al., “Validation of MAF biomarker for response prediction to adjuvant bisphosphonates in 2 clinical trials: AZURE and NSABP-B34—Abstract 513,” J. Clinical Oncology 38(15_Suppl): Abstract 513, American S… [cited by applicant]
Chothia, C., and Lesk, A.M., “Canonical structures for the hypervariable regions of immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier, Netherlands (Aug. 1987). [cited by applicant]
Holliger, P., and Hudson, P.J., “Engineered antibody fragments and the rise of single domains,” Nature Biotechnology 23(9):1126-1136, Nature America Publishing, United States (Sep. 2005). [cited by applicant]
Chothia, C., et al., “Conformations of immunoglobulin hypervariable regions,” Nature 342(6252):877-883, Nature Publishing Group, United Kingdom (Dec. 1989). [cited by applicant]
Amit, A.G., et al., “Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution,” Science 233(4765):747-753, American Association for the Advancement of Science, United States (1986). [cited by applicant]
Caton, A.J., et al., “Identical D Region Sequences Expressed by Murine Monoclonal Antibodies Specific for a human Tumor-associated Antigen,” Journal of Immunology 144(5):1965-1968, American Association of Immunologists,… [cited by applicant]
Segal, D.M., et al., “The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site,” Proceedings of the National Academy of Sciences of the United St… [cited by applicant]
Sharon, J., “Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold,” Proceedings of the National Academy of… [cited by applicant]
Sharon, J., “Structural characterization of idiotopes by using antibody variants generated by site-directed mutagenesis,” Journal of Immunology 144(12):4863-4869, American Association of Immunologists, United States (Ju… [cited by applicant]
Viprey, V.F., et al., “Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study,” Journal of Clinical Oncology, 32(10):1074-1083, American Society of Clinical Oncoogy, … [cited by applicant]
Martin, M., “Benefit of denosumab therapy in patients with bone metastases from breast cancer: a number-needed-to-treat (NNT) analysis,” Breast (Edinburgh, Scotland) (BREAST) 20(1):S85, Abstract P347, accessed at URL:[h… [cited by applicant]
Drake, M.T., et al., “Bisphosphonates: mechanism of action and role in clinical practice,” Mayo Clin Proc 83(9):1032-1045, Elsevier, Netherlands (Sep. 2008). [cited by applicant]
Gralow, J.R., et al., “Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307,” J Natl Cancer Inst 112(7):698-707, Oxford University Press, United Kingdom (Jul. 2020). [cited by applicant]
Paterson, A.H.G., et al., “MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice,” JNCI Cancer Spectr 5(4):pkab054, Oxford University Pre… [cited by applicant]
Reis-Filho, J.S., “Triple Negative and Basal-like Breast Cancer: One or Many diseases? Implications for surgical Pathologists,” accessed at https://web.archive.org/web/20130319192034/http://www.uscap.org/site˜/98th/pdf/… [cited by applicant]
Zhao, X., and Hu, X., “Dosing of Zoledronic Acid with its Anti-Tumor Effects in Breast Cancer,” Journal of Bone Oncology 4(3):98-101, Elsevier, Netherlands (Oct. 2015). [cited by applicant]
Rosen, L.S., et al., “Zoledronic Acid is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients With at Least One Osteolytic Lesion,” Cancer 100(1):36-43, Wiley, United States (Jan. 20… [cited by applicant]
Kristensen, B., et al., “Oral Clodronate in Breast Cancer Patients with Bone Metastases: A Randomized Study,” Journal of Internal Medicine, 246(1):67-74, Blackwell Scientific Publications, United Kingdom (Jul. 1999). [cited by applicant]
Zefei, J., et al., “Expert Consensus on Clinical Diagnosis and Treatment of Breast Cancer Bone Metastasis and Bone-related Diseases (2014 Edition),” Chinese Medical Journal, 95(4):241-247, Wolters Kluwer Medknow Publica… [cited by applicant]
Baker, S.G., “The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer,” Journal of the National Cancer Institute 95(7):511-515, Oxford University Press, U… [cited by applicant]
Haas, D, “On the Expanding, Then Contracting Scope of Scientific Publications,” FEMS Microbiology Reviews 34(1):1-2, Oxford University Press, England (Jan. 2010). [cited by applicant]
Furukawa, H., et al., “Analysis of the Risk and Work Efficiency in Admixture Processes of Injectable Drugs using the Ampule Method and the Pre-filled Syringe Method,” Japanese Journal of Pharmaceutical Health Care and S… [cited by applicant]
Ezra, A., et al., “Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption,” Adv Drug Deliv Rev., 42(3): 175-195 (2000). [cited by applicant]
Anonymous, “Highlights of Prescribing Information—Zometa (zoledronic acid)”, XP055980793, pp. 1-23 (2014). [cited by applicant]
Anonymous, “Product information Bonefos (sodium clodronate)”, XP055980801, pp. 1-12 (Mar. 2012). [cited by applicant]
Co-pending Application, U.S. Appl. No. 18/169,537, inventors Gregory. W.M., et al., filed Feb. 15, 2023 (Not yet Published). [cited by applicant]
Co-pending Application, U.S. Appl. No. 18/154,295, inventors Gomis. R., et al., filed Jan. 13, 2023 (Not yet Published). [cited by applicant]
Co-pending Application, U.S. Appl. No. 18/298,807, inventors Gregory. W.M., filed Apr. 11, 2023 (Not yet Published). [cited by applicant]
Costa, L., “Bisphosphonates: reducing the risk of skeletal complications from bone metastasis,” Breast 16(Suppl 3):S16-20 (Dec. 2007). [cited by applicant]